Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer: a French Observational Multicenter Study of 259 Patients (ABCT-IMMUNOBZH)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04858204

Acronym

IMMUNOBZH

Enrollment

259

Registered

2021-04-26

Start date

2017-04-14

Completion date

2017-11-01

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Keywords

Real-life, nivolumab

Brief summary

Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice. Investigators aimed at assessing efficacy and safety of nivolumab in a real-life setting and determining a subtype of NSCLC patients that are more likely to benefit from immunotherapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* advanced NSCLC (stage IIIB-IV) * failure of at least one line of chemotherapy. * age ≥18 years, * initiation of nivolumab between 01/09/2015 and 30/09/2016.

Exclusion criteria

* nivolumab initiation after October 2016 * prior involvement in an immunotherapy trial * refusal to participate.

Design outcomes

Primary

Measure	Time frame	Description
Nivolumab Objective response rate	through study completion, an average of 1 year	Objective response rate evaluated by RECIST 1.1

Countries

France

Outcome results